Double Unrelated Reduced-intensity Umbilical Cord Blood Transplantation in Adults
Overview
Authors
Affiliations
Umbilical cord blood (UBC) stem cells are a useful stem cell source for patients without matched related or unrelated donors. Adult transplantation with single UBC units is associated with high transplantation-related mortality (TRM). In most cases, mortality is due to infection related to slow engraftment and immunoincompetence. In this study, we used a reduced-intensity conditioning regimen of fludarabine, melphalan, and antithymocyte globulin followed by 2 partially matched UBC units. The UBC units were a 4/6 HLA match or better with each other and with the patient and achieved a minimum precryopreservation cell dose of 3.7 x 10(7) nucleated cells/kg. A total of 21 patients (median age, 49 years) were treated. The median time to an absolute neutrophil count > 0.5 x 10(9)/L was 20 days, and the median time to an unsupported platelet count > 20 x 10(9)/L was 41 days. Two patients experienced primary graft failure and underwent a second UBC transplantation. One patient had a late graft failure. Acute graft-versus-host disease (GVHD) grade II-IV occurred in 40% of patients. The 100-day TRM was 14%, and the 1-year disease-free survival was 67%. Mixed chimerism was associated with a higher risk of chronic GVHD. Our findings indicate that adult patients can tolerate double UBC transplantation well and achieve sustained antitumor responses using this reduced-intensity conditioning regimen.
Mathews D, Abernethy A, Chaikof E, Charo R, Daley G, Enriquez J NAM Perspect. 2024; 2023.
PMID: 38855738 PMC: 11157685. DOI: 10.31478/202311d.
Umbilical Cord Blood Transplantation: Connecting Its Origin to Its Future.
Sanchez-Petitto G, Rezvani K, Daher M, Rafei H, Kebriaei P, Shpall E Stem Cells Transl Med. 2023; 12(2):55-71.
PMID: 36779789 PMC: 9985112. DOI: 10.1093/stcltm/szac086.
Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe.
Rafii H, Ruggeri A, Kenzey C, Sanz J, Peffault De La Tour R, Esquirol A Blood Adv. 2022; 7(10):1976-1986.
PMID: 36350759 PMC: 10189403. DOI: 10.1182/bloodadvances.2022007941.
Murata M, Kawabe K, Hatta T, Maeda S, Fujita M BMC Med Ethics. 2022; 23(1):92.
PMID: 36096840 PMC: 9465943. DOI: 10.1186/s12910-022-00830-8.
Hough R, Lopes A, Patrick P, Russell N, Raj K, Tholouli E Blood Adv. 2021; 6(7):2414-2426.
PMID: 34700343 PMC: 9006284. DOI: 10.1182/bloodadvances.2021005106.